Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF NanomedicineLIBUTTI, Steven K; PACIOTTI, Giulio F; BYRNES, Adriana A et al.Clinical cancer research (Print). 2010, Vol 16, Num 24, pp 6139-6149, issn 1078-0432, 11 p.Article

Benign form of atrophic papulosis developed at injection sites of pegylated-alpha-interferon: is there a pathophysiological link?ZAHARIA, D; TRUCHOT, F; RONGER-SAVLE, S et al.British journal of dermatology (1951). 2014, Vol 170, Num 4, pp 992-994, issn 0007-0963, 3 p.Article

Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy : patients' views of early cessation of therapyD'SOUZA, R; MAIN, J; CROSSEY, M et al.Alimentary pharmacology & therapeutics. 2005, Vol 21, Num 1, pp 43-47, issn 0269-2813, 5 p.Article

Serum-stable and long-circulating, PEGylated, pH-sensitive liposomesROUX, Emmanuelle; PASSIRANI, Catherine; SCHEFFOLD, Stefanie et al.Journal of controlled release. 2004, Vol 94, Num 2-3, pp 447-451, issn 0168-3659, 5 p.Article

Pegylated liposomal doxorubicin-induced palmar-plantar erythrodysestesia in multiple uncommon sitesCORAZZA, Monica; MINGHETTI, Sara; ZAULI, Stefania et al.EJD. European journal of dermatology. 2011, Vol 21, Num 3, pp 433-434, issn 1167-1122, 2 p.Article

Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicinHAIFENG SONG; JIN ZHANG; ZHIKAI HAN et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 5, pp 591-598, issn 0344-5704, 8 p.Article

Erupción intertriginosa por doxorrubicina liposomal pegilada = Intertriginous Rash Caused by Pegylated Liposomal DoxorubicinMONTEAGUDO, B; AFONSO-AFONSO, F. J; CABANILLAS, M et al.Actas dermo-sifiliográficas (Ed. impresa). 2009, Vol 100, Num 3, pp 241-243, issn 0001-7310, 3 p.Article

Dose―response effects of PEGylated cholecystokinin on the behavioral satiety sequenceVERBAEYS, I; LEON-TAMARIZ, F; DE BUYSER, K et al.Physiology & behavior. 2009, Vol 98, Num 1-2, pp 198-204, issn 0031-9384, 7 p.Article

Eccrine Squamous Syringometaplasia Secondary to Pegylated Liposomal DoxorubicinGARCIA-NAVARRO, Xavier; PUIG, Lluis; FERNANDEZ-FIGUERAS, Maria T et al.Archives of dermatology (1960). 2008, Vol 144, Num 10, pp 1402-1403, issn 0003-987X, 2 p.Article

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraKILADJIAN, Jean-Jacques; CASSINAT, Bruno; CHEVRET, Sylvie et al.Blood. 2008, Vol 112, Num 8, pp 3065-3072, issn 0006-4971, 8 p.Article

Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulinSHIRUI MAO; BAKOWSKY, Udo; JINTAPATTANAKIT, Anchalee et al.Journal of pharmaceutical sciences. 2006, Vol 95, Num 5, pp 1035-1048, issn 0022-3549, 14 p.Article

CASE 2. Splenic rupture following pegfilgrastimARSHAD, Muhammad; SEITER, Karen; BILANIUK, Jaroslaw et al.Journal of clinical oncology. 2005, Vol 23, Num 33, pp 8533-8534, issn 0732-183X, 2 p.Article

PEGylated recombinant human interferon-ω as a long-acting antiviral agent: Structure, antiviral activity and pharmacokineticsWEILI YU; CHANGMING YU; LING WU et al.Antiviral research. 2014, Vol 108, pp 142-147, issn 0166-3542, 6 p.Article

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid responseNEUKAM, Karin; BARREIRO, Pablo; RIVERO-JUAREZ, Antonio et al.The Journal of infection. 2013, Vol 67, Num 1, pp 59-64, issn 0163-4453, 6 p.Article

Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomesGABIZON, Alberto A; TZEMACH, Dinah; HOROWITZ, Aviva T et al.Clinical cancer research. 2006, Vol 12, Num 6, pp 1913-1920, issn 1078-0432, 8 p.Article

Interféron alfa, peginterféron alfa et rétinopathie = Interferon alpha, peginterferon alpha and retinopathyLa Revue Prescrire. 2005, Vol 25, Num 264, pp 591-592, issn 0247-7750, 2 p.Article

Temoporfin-loaded liposomes: Physicochemical characterizationKUNTSCHE, Judith; FREISLEBEN, Ines; STEINIGER, Frank et al.European journal of pharmaceutical sciences. 2010, Vol 40, Num 4, pp 305-315, issn 0928-0987, 11 p.Article

Thyrotoxicosis With Pegylated Interferon Alfa-2bLOWNDES, Sarah A; ASHER, Ruth; MIDDLETON, Mark R et al.Archives of dermatology (1960). 2010, Vol 146, Num 11, pp 1273-1275, issn 0003-987X, 3 p.Article

Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced MalignanciesZAMBONI, W. C; STRYCHOR, S; RAMANATHAN, R. K et al.Clinical pharmacology and therapeutics. 2009, Vol 86, Num 5, pp 519-526, issn 0009-9236, 8 p.Article

Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced MalignanciesZAMBONI, William C; RAMALINGAM, Suresh; FRIEDLAND, David M et al.Clinical cancer research (Print). 2009, Vol 15, Num 4, pp 1466-1472, issn 1078-0432, 7 p.Article

What the Infectious Disease Physician Needs to Know About Pegylated Interferon and RibavirinGARA, Naveen; GHANY, Marc G.Clinical infectious diseases. 2013, Vol 56, Num 11, pp 1629-1636, issn 1058-4838, 8 p.Article

Pegylation of Antimicrobial Peptides Maintains the Active Peptide Conformation, Model Membrane Interactions, and Antimicrobial Activity while Improving Lung Tissue Biocompatibility following Airway DeliveryMORRIS, Christopher J; BECK, Konrad; FOX, Marc A et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3298-3308, issn 0066-4804, 11 p.Article

Surface assembly of poly(I:C) on PEGylated microspheres to shield from adverse interactions with fibroblastsHAFNER, Annina M; BURSCHOWSKY, Daniel; CORTHESY, Blaise et al.Journal of controlled release. 2012, Vol 159, Num 2, pp 204-214, issn 0168-3659, 11 p.Article

Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literatureLOPEZ, Verónica; MOLINA, Inmaculada; MONTEAGUDO, Carlos et al.International journal of dermatology. 2011, Vol 50, Num 3, pp 287-291, issn 0011-9059, 5 p.Article

Design, synthesis and anti-inflammatory evaluation of PEGylated 4-methyl and 4,8-dimethylcoumarinsPANDEY, Mukesh K; BALWANI, Sakshi; SHARMA, Pramod K et al.European journal of pharmaceutical sciences. 2010, Vol 39, Num 1-3, pp 134-140, issn 0928-0987, 7 p.Article